FDA Grants Priority Review For VEGF Trap-Eye For The Treatment Of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). The FDA also granted the Company's request for priority review of its BLA. A Priority Review designation is ...

Medical device approvals criticised
WASHINGTON - Government investigators say the Food and Drug Administration is putting patients at risk by approving sensitive medical devices such as hip joints and heart defibrillators under the same streamlined system intended for power wheelchairs, stitches and catheters.